Q2 EPS Estimate for Exact Sciences Increased by Analyst

Exact Sciences Co. (NASDAQ:EXAS - Free Report) - Stock analysts at Leerink Partnrs raised their Q2 2025 earnings per share estimates for shares of Exact Sciences in a research note issued to investors on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings of $0.03 per share for the quarter, up from their prior forecast of $0.02. The consensus estimate for Exact Sciences' current full-year earnings is ($1.13) per share.

Several other analysts have also commented on the stock. Stifel Nicolaus lowered their price objective on shares of Exact Sciences from $82.00 to $67.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. TD Cowen raised their target price on Exact Sciences from $82.00 to $86.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Sanford C. Bernstein upped their price target on Exact Sciences from $75.00 to $90.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Canaccord Genuity Group lowered their price objective on Exact Sciences from $95.00 to $75.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. Finally, Benchmark reduced their target price on shares of Exact Sciences from $67.00 to $65.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $72.94.

Exact Sciences Trading Down 0.7 %

Shares of NASDAQ:EXAS traded down $0.42 on Wednesday, hitting $56.68. The company had a trading volume of 2,499,536 shares, compared to its average volume of 1,840,427. The firm's 50-day simple moving average is $58.61 and its two-hundred day simple moving average is $58.59. The firm has a market capitalization of $10.49 billion, a price-to-earnings ratio of -48.44 and a beta of 1.24. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. Exact Sciences has a 1 year low of $40.62 and a 1 year high of $79.62.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). The business had revenue of $708.66 million for the quarter, compared to the consensus estimate of $716.80 million. Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. The business's revenue was up 12.8% compared to the same quarter last year.

Institutional Investors Weigh In On Exact Sciences

A number of large investors have recently made changes to their positions in the company. William Blair Investment Management LLC bought a new position in Exact Sciences in the second quarter worth approximately $163,896,000. Geode Capital Management LLC increased its stake in shares of Exact Sciences by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 3,105,970 shares of the medical research company's stock worth $211,104,000 after purchasing an additional 7,873 shares in the last quarter. Champlain Investment Partners LLC raised its holdings in Exact Sciences by 10.9% in the 3rd quarter. Champlain Investment Partners LLC now owns 2,494,480 shares of the medical research company's stock worth $169,924,000 after purchasing an additional 245,980 shares during the period. Bellevue Group AG lifted its position in Exact Sciences by 25.1% during the third quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company's stock valued at $98,738,000 after purchasing an additional 290,585 shares in the last quarter. Finally, Armistice Capital LLC grew its holdings in Exact Sciences by 91.6% during the second quarter. Armistice Capital LLC now owns 1,400,086 shares of the medical research company's stock valued at $59,154,000 after purchasing an additional 669,438 shares during the period. 88.82% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Kevin T. Conroy acquired 19,500 shares of the business's stock in a transaction that occurred on Wednesday, November 13th. The stock was bought at an average price of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,074,191 shares of the company's stock, valued at approximately $55,159,707.85. The trade was a 1.85 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.36% of the stock is owned by corporate insiders.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.